Expert panelists explore challenges impacting care access for patients with MDS. Ryan Haumschild, PharmD, MS, MBA: Dr Fazal, what are some of the challenges surrounding access to care? I highlighted a ...

Dr. Timothy Olson, a pediatric hematologist at Children's Hospital of Philadelphia, discusses the most current thinking on treatment of children with aplastic anemia. This video was recorded at the ...

Reblozyl for anemia in patients with an MDS subset demonstrated positive effects, compared with previous treatments, according to an MDS expert. Treatment with Reblozyl (luspatercept-aamt) was ...

Patterns revealed by Minimum Data Set entries and what they unearth about patient care can help providers perform better on quality measures, if that data is used to better understand and act on ...

Myelodysplastic syndromes (MDS) are blood cancers where bone marrow makes too few healthy blood cells. Many of the cells produced die early or do not function normally. Early myelodysplastic syndromes ...

Myelodysplastic syndromes (MDS) are blood cancers caused by an insufficient production of healthy blood cells. Production of irregular cells leads to anemia, where the body’s organs and tissues don’t ...

Myelodysplastic syndromes (MDS) are a group of disorders in which a person’s bone marrow does not produce enough functioning blood cells. MDS is a type of cancer that damages some of the blood-forming ...